ICU Stock Forecast 2025-2026
Distance to ICU Price Targets
ICU Price Momentum
10 Quality Stocks Worth Considering Now
Researching SeaStar (ICU) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on ICU and similar high-potential opportunities.
Latest ICU Stock Price Targets & Analyst Predictions
Based on our analysis of 1 Wall Street analyst, ICU has a bullish consensus with a median price target of $7.00 (ranging from $7.00 to $7.00). Currently trading at $1.25, the median forecast implies a 460.0% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ICU Analyst Ratings
ICU Price Target Range
Latest ICU Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ICU.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 20, 2023 | Maxim Group | Anthony Vendetti | Buy | Initiates | $5.00 |
Seastar Medical Holding Corporation (ICU) Competitors
The following stocks are similar to SeaStar based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Seastar Medical Holding Corporation (ICU) Financial Data
Seastar Medical Holding Corporation has a market capitalization of $10.90M with a P/E ratio of 0.0x. The company generates $135,000 in trailing twelve-month revenue with a 100.0% profit margin.
Revenue growth is -1.5% quarter-over-quarter, while maintaining an operating margin of -7,114.9% and return on equity of +1,137.4%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Seastar Medical Holding Corporation (ICU) Business Model
About Seastar Medical Holding Corporation
Develops medical devices for acute kidney and sepsis conditions.
Seastar Medical generates revenue by developing and selling innovative medical devices that address life-threatening conditions such as acute kidney injury and sepsis. The company collaborates with healthcare institutions to create therapies that are rigorously validated and compliant with regulatory standards.
Headquartered in the United States, Seastar Medical is focused on enhancing patient outcomes through advanced therapies. Its pivotal products target significant unmet medical needs, positioning the company as a key player in the healthcare technologies market.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
19
CEO
Mr. Eric Schlorff
Country
United States
IPO Year
2022
Website
www.seastarmedical.comSeastar Medical Holding Corporation (ICU) Latest News & Analysis
SeaStar Medical received FDA Breakthrough Device Designations for its Selective Cytopheretic Device therapy, aimed at reducing post-operative complications in adult and pediatric cardiac surgery patients.
FDA Breakthrough Designations for SeaStar's SCD therapy could significantly enhance its market position, driving potential revenue growth and attracting investor interest in the healthcare sector.
SeaStar Medical Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
23 days agoSeaStar Medical reported its financial results for Q4 and the year ended December 31, 2024. The company aims for significant growth in 2025, according to CEO Eric Schlorff.
SeaStar Medical's financial results and positive outlook for 2025 signal growth potential, which could influence stock performance and attract investor interest in the healthcare sector.
SeaStar Medical to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025
26 days agoSeaStar Medical Holding Corporation (Nasdaq: ICU) will report Q4 and year-end 2024 financial results on March 27, 2025, followed by a webcast and conference call for discussion.
SeaStar Medical's upcoming financial results could influence stock performance, revealing insights into its growth, operational efficiency, and market position in healthcare for organ failure.
SeaStar Medical (Nasdaq: ICU) has been awarded the 2025 Corporate Innovator Award by the National Kidney Foundation for its treatment approved for pediatric acute kidney injury due to sepsis.
SeaStar Medical's award and new treatment approval could enhance its market position, potentially driving stock value and attracting investor interest in the company's growth prospects.
SeaStar Medical Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market
2 months agoSeaStar Medical closed a registered direct offering, selling 3,529,412 shares of common stock to an institutional investor, along with warrants for the same number of shares.
SeaStar Medical's direct offering and concurrent private placement indicate confidence in funding and may impact share dilution, influencing stock value and investor sentiment.
SeaStar Medical (Nasdaq: ICU) announced Mayo Clinic is cleared to enroll subjects in its NEUTRALIZE-AKI pivotal trial, expanding activated sites to 15.
Mayo Clinic's approval to enroll subjects in SeaStar's pivotal trial signals increased momentum for the company's product development, potentially boosting investor confidence and stock value.
Frequently Asked Questions About ICU Stock
What is Seastar Medical Holding Corporation's (ICU) stock forecast for 2025?
Based on our analysis of 1 Wall Street analysts, Seastar Medical Holding Corporation (ICU) has a median price target of $7.00. The highest price target is $7.00 and the lowest is $7.00.
Is ICU stock a good investment in 2025?
According to current analyst ratings, ICU has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.25. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ICU stock?
Wall Street analysts predict ICU stock could reach $7.00 in the next 12 months. This represents a 460.0% increase from the current price of $1.25. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Seastar Medical Holding Corporation's business model?
Seastar Medical generates revenue by developing and selling innovative medical devices that address life-threatening conditions such as acute kidney injury and sepsis. The company collaborates with healthcare institutions to create therapies that are rigorously validated and compliant with regulatory standards.
What is the highest forecasted price for ICU Seastar Medical Holding Corporation?
The highest price target for ICU is $7.00 from at , which represents a 460.0% increase from the current price of $1.25.
What is the lowest forecasted price for ICU Seastar Medical Holding Corporation?
The lowest price target for ICU is $7.00 from at , which represents a 460.0% increase from the current price of $1.25.
What is the overall ICU consensus from analysts for Seastar Medical Holding Corporation?
The overall analyst consensus for ICU is bullish. Out of 1 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $7.00.
How accurate are ICU stock price projections?
Stock price projections, including those for Seastar Medical Holding Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.